An article published last week in Scientific Reports describes the results of a multicenter prospective study evaluating the safety and efficacy of switching IBD patients from Abbvie’s Humira product to either of two adalimumab biosimilars, ABP501 (Amgen) and SB5 (Samsung Bioepsis).  The authors concluded from this study that both biosimilars seem to be as safe and effective as the originator, although a significant percentage of patients that switched to ABP501, but not to SB5, required steroid supplementation.